Neonatal hypoglycemia and hyperglycemia BY Dr VIJITHA A S
Hypoglycemia is most common metabolic problem seen in newborns
No universally accepted definition ; Hypoglycemia cut off variable
pediatrics emergency, hypoglycemia of infancy.
Glucose level can drop if:
There is too much insulin in the blood (hyperinsulinism). Insulin is a hormone that pulls glucose from the blood.
The baby is not producing enough glucose.
The baby's body is using more glucose than is being produced.
The baby is not able to feed enough to keep glucose level up.
pediatrics emergency, hypoglycemia of infancy.
Glucose level can drop if:
There is too much insulin in the blood (hyperinsulinism). Insulin is a hormone that pulls glucose from the blood.
The baby is not producing enough glucose.
The baby's body is using more glucose than is being produced.
The baby is not able to feed enough to keep glucose level up.
Gastroesophageal reflux disease in children.Indian Society of Pediatric Gast...Vijitha A S
Gastroesophageal reflux disease in children.Indian Society of Pediatric Gastroenterology, Hepatology and Nutrition (ISPGHAN) 2022 update
DR VIJITHA A S
Hemophagocytic lymphohistiocytosis (hlh), Langerhans cell histiocytosis dr vi...Vijitha A S
Hemophagocytic lymphohistiocytosis (hlh)
Langerhans cell histiocytosis,Benign proliferation of mature histiocytes and uncontrolled phagocytosis of the platelet, erythrocytes, lymphocytes, and their hematopoietic precursors in the bonemarrow & other tissues
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
3. PHYSIOLOGY OF GLUCOSE HOMEOSTASIS IN
THE NEWBORN
During pregnancy, the fetus is dependent on the mother for a constant supply of glucose. All
Fetal Glucose is derives from maternal circulation by facilitated diffusion.
Maternal insulin does not cross the placenta and the fetus makes its own insulin to maintain
blood glucose levels.
Both in utero and in postnatal life, insulin secretion from the beta cells is tightly linked to
plasma glucose concentrations.
Enzymes for gluconeogenesis, presented by 3rd month of gestation.
Insulin starts production by 12 Weeks and increases third trimester
Glucagon starts production by15 weeks of gestation.
The fetus stores glucose in the form of glycogen (liver, heart, lung, and skeletal muscle). Most
of the glycogen is made and stored in the last month of the 3rd trimester
4. When the Plasma glucose concentration drops below 80 to 85 mg/dL, still within
the physiological range, the first response is to shut off insulin secretion to prevent
further decrease in glucose levels.
The decrease in insulin removes the inhibitory effect on lipolysis and ketogenesis,
thereby providing alternative fuel sources.
Hepatic glycogen serves as the first and immediate source of glucose. With a
decrease in plasma glucose levels, the increase in glucagon and epinephrine
levels promotes hepatic glycogenolysis and provides a source of glucose for a few
hour
5. Epinephrine also inhibits insulin secretion and stimulates glucagon release from the
pancreatic islets.
Beta-oxidation of fatty acids (mediated through actions of epinephrine and glucagon) results
in the formation of ketone bodies, an alternative energy source for the brain
Cortisol, along with epinephrine, increases gluconeogenesis from non-carbohydrate sources
such as alanine, lactate, and glycerol
The purpose of these complex systems is to maintain PG within age-appropriate physiologic
ranges and to avoid hypoglycemia-related negative outcomes
8. Metabolic actions of insulin include - increase in cellular glucose
uptake, deposition of glucose as glycogen, lipogenesis in adipose
tissue, and inhibition of breakdown of triglycerides (lipolysis)
and fatty acids (ketone body formation or ketogenesis).
Insulin is a major fetal growth factor.
9. DEFENITION
Hypoglycemia is most common metabolic problem seen in newborns
No universally accepted definition ; Hypoglycemia cut off variable
Clinical Definition of Hypoglycemia
defined as a Plasma glucose concentration low enough to cause
symptoms and/or signs of impaired brain function
10. Classical Defenition –blood sugar <40mg/dl or <2.6mmol/l (whole blood)
AAP DEFENITION
Symtomatic - < 40mg/dl
Asymtomatic - First 4 hours of life <25mg/dl
4-24 hours of life <35mg/dl
>24 hours of life <45mg/dl
Target after 48 hours of life >60 mg/dl ;
- symptomatic/asphyxia - >70mg/dl
11. INCIDENCE
Overall Incidence = 1- 5/1000 live births
Normal newborns – 10% if feeding is delayed for 3-6 hours after birth
At-Risk Infants –
LGA – 16%
Preterm – 15%
SGA – 15%
IDM – 20%
12. HIGH RISK GROUP
Preterm
SGA
LGA
IDM - presence of high circulating
insulin levels and a delay in
glucagon increase
Sick babies
Rh isoimmunization
Infants on TPN
2 hours of post DVET
Maternal beta blockers
Midline defect
14. TRANSIENT HYPOGLYCEMIA
Developmental immaturity in adaptation to fasting: Prematurity, SGA
Stress in peripartum/postnatal period: Trauma, asphyxia, hypothermia
Transient hyperinsulinemia: IDM, Intrapartum dextrose infusion to
mother.
Increased metabolic expenditure: Sepsis, Erythroblastosis fetalis,
Polycythemia
Other maternal conditions: Toxaemia, administration of tocolytics ( β
sympatho mimetics)
15. II.REFRACTORY HYPOGLYCEMIA/PROLONGED
HYPOGLYCEMIA
Refractory hypoglycemia
If the infant remains hypoglycemic despite receiving glucose
infusion of
>12mg/kg/min
Prolonged hypoglycaemia/ Persistent hypoglycemia
if need for glucose infusion persists for >7days
Hyperinsulinism is the most common cause of persistent
17. 1.HYPERINSULINEMIC HYPOGLYCEMIA
Causes persistent recurrent hypoglycemia in newborns
Associated with increased risk of brain injury by decreases serum blood glucose levels, preventing
brain from utilizing secondary fuel sources by suppressing fatty acid synthesis and ketone body
synthesis.
IDM is the most common example of transient hyperinsulinism.
Hyperinsulinism is seen in mutation of genes encoding the pancreatic beta cell ATP sensitive
potassium channel -ABCC8, KCNJ11, HNF4A gene
18. Hyperinsulinism secondary to other
conditions
Syndromes –Beck with-Wiedmann syndrome (macrosomia, mild microcephaly, omphalocele,
macroglossia, hypoglycemia and visceromegaly).
congenital disorders of glycosylation and metabolic condition
Erythroblastosis
After exchange transfusion with blood containing high glucose concentration
Insulin producing tumours( nesidioblastosis, islet cell adenoma, islet cell dysmaturity)
19.
20. 2. DEREASED SUBSTRATE/PRODUCTION
Prematurity
IUGR - decreased glycogen stores at birth, low fat stores that further increase their risk
for fuel insufficiency.
SGA
Delayed onset of feeding
Inadequate caloric intake
21. 3. INCREASED DEMAND
Perinatal stress – sepsis ,shock, asphyxia, hypothermia , respiratory distress,
post resuscitation
Polycythemia- higher glucose utilization by increased mass of RBC.
Maternal or infant therapy with beta blockers –
mechanism - prevention of sympathetic stimulation of glycogenolysis.
- prevention of recovery from insulin induced decrease in fatty acids and glycerol
- inhibition of epinephrine induced increases in in free fatty acids and lactate after exercise
.
22. INBORN ERROR OF METABOLISMS
Defect in carbohydrate metabolism - Glycogen storage disorder
- Fructose intolerance
- Galactosemia
Defect in amino acid metabolism - Maple syrup urine disease
- Propionic academia
- Methylmalonic academia
- Tyrosenemia
ENDOCRINE DEFICIENCY-
- Adrenal insufficiency
- Hypothalamic deficiency
- Congenital hypopituitarism
- Glucagon deficiency
- Epinephrin deficiency
24. SCREENING
Serial blood sugar levels should be routinely measured in infants who have
risk factors for hypoglycaemia or infants who have symptoms suggestive
of hypoglycaemia
25.
26. Schedule of blood monitoring
Category of infants Time schedule
1 At risk neonates(LBW, PT, SGA, IUGR,IDM, Rh
,maternal drugs)
0,2,6,12,24,48,and 72 h of
life
2 Sick neonates(sepsis, asphyxia, polycythemia,
shock during acute phase illness)
Every 6-8 hours
3 Neonates on parentral nutrition Initial 72 hours – 6-8 hours
After 72 hours – once a day
27. METHODS OF BLOOD GLUCOSE
ESTIMATION
I POINT OF CARE GLUCO- METER:
Widely used glucose estimation method, they are useful for screening
purpose, low values should be confirmed by laboratory testing(<45mg/dl)
Treatment of hypoglycemia should be initiated based on the results of reagent
strips without waiting for laboratory reports.
Arterial sample blood sugar value > venous blood > capillary blood
whole blood glucose values are 15% lower than plasma glucose
concentrations.
28. 1st generation strips – change in color by enzymatic reaction on application
of blood drop
Color can be read by reflectance meters or naked eye.
The results get affected by hematocrit values, acidosis, bilirubin
Newer generation glucose reagent strips : generate current on reaction of
glucose with enzymes such as Glucose oxidase/ glucose dehydrogenase
Amount of current is proportion to amount of sugar in plasma
29. II LABORATORY DIAGNOSIS
Gold standard for measuring blood glucose
Blood glucose measured by glucose oxidase method or glucose electrode
method
Prompt analysis should be performed – reduction of glucose up to
6mg/dl/hr in a blood sample that awaits analysis.
30. III SUBCUTANEOUS CONTINUOUS
GLUCOSE MONITORING SENSORS(CGMS)
Have been used in glucose monitoring in newborns
Helps in detection of hypoglycemia, that missed on routine screening
CGMS require insertion of platinum sensor in subcutaneous tissue – increase the risk of
infection.
Interstitial glucose is catalyzed and electrical current is produced every 10 second
Primarily used in research settings, studies required to determine the efficacy and safety
in neonatal population.
33. HYPOGLYCEMIA MANAGEMENT
Anticipation and prevention are key to the management of infants at risk for
hypoglycemia.
The goal in the management of neonatal hypoglycemia is to restore plasma
glucose levels to a safe, age-appropriate range.
Enteral feeding should be instituted in all newborns as quickly as possible unless
there are contraindications because of other morbidities
When hypoglycemia persists on a typical feeding regimen, more frequent feeding
regimens or use of calorically dense formulas or fortification of breast milk may
be tried.
34. Newborns with risk factors for hypoglycemia should receive oral feeding
within 1 hour after birth
Breastfeeding - enhances gluconeogenesis and increases the production of
glucogenic precursors.
-keep ketones levels high alternate fuel during first few days while
baby adapts to DBF.
DEXTROSE GEL (40%) – To treat mild hypoglycemia in infants at risk
for hypoglycemia
- Under trial now.
35. Intravenous Dextrose
Intravenous dextrose is the treatment of choice for acute management, when enteral feeding is
contraindicated or the newborn suffers from symptomatic or severe hypoglycemia,
The standard approach is to give a 2 mL/kg (200 mg/kg) bolus of 10% dextrose followed by a
continuous dextrose infusion to achieve euglycemia
Start GIR at 6mg/kg/min ; target blood sugar is >60mg/dl
Blood glucose should be checked after 30 minute and then every 6 hours until blood glucose
>60mg/dl
If Blood glucose below 60mg/dl despite bolus and glucose infusion - GIR should Increased in
2mg/kg/min every 15 -30 minute until maximum of 12mg/kg/min.
36. Tapering
After 24 hours of IV glucose therapy, two or more consecutive blood glucose
are >60mg/dl, the infusion can be tapered off at the rate of 2mg/kg/min every
6 hours with blood glucose monitoring
Tapering has to be accompanied by concomitant increase in oral feeds
Once GIR of 4mg/kg/min is achieved , oral intake is adequate and the BGL
are consistently >60 mg/dl , the infusion can be stopped.
Do not stop glucose infusion abruptly as severe rebound hypoglycemia may
occur
37. GLUCOSE INFUSION RATE ( GIR)
GIR= dextrose % concentration × ml/kg/day
144
Dextrose % = 144*GIR
ml/kg/day
infusion of glucose is usually maintained at 6 to 8 mg/kg/min
38.
39. BASIC APPROACH REFRACTORY HYPOGLYCEMIA
Non ketotic Ketotic
High Insulin Low insulin
Normal
ammonia
pancreatic
Βeta cell mutations
High
ammonia
GLUD1
mutaions
Free fatty acid
oxidation
defects
High lactate
Normal
lactate
• Hypopitutarism
• Isolated GH
deficiency
• CAH
• Organic aciduria
• Disord- gluconeogenesis
• Glycogen storage
disorders
41. MANAGEMENT OF PERSISTENT
HYPOGLYCEMIA cont…
Treat the cause eg; Endocrine and glucogenic and glycogenic disorder
Maximize the GIR
Medications : Hydrocortisone / Diazoxide / Octreotide /Glucagon / sirolimus
Surgery – partial and subtotal pancreatectomy
42. DRUGS USED IN MANAGEMENT OF RESISTANT
HYPOGLYCEMIA
DRUGS DOSE ROUTE MODE OF ACTION SIDE EFFECTS
Hydrocortisone 5mg/kg/day
2 divided dose
PO/IV • Reduces peripheral
glucose utilization
• Increases gluconeogenesis
• Increase glucagon effect
Hyperglycemia
Hypertension
Diazoxide 5-15mg/kg/day
TDS
PO K channel agonist Fluid retention
Hypertrichosis
Cardiac failure
Octreotide 5-35mcg/kg/day
TDS/QID
PO Somatostatin analogue
inhibits insulin secretion
Cholelithiasis
Transient growth
impairment
Tachyphylaxis
Glucagon 0.2 mg/kg SC or IM Glycogenolysis
Increased gluconeogenesis
nausea
Vomiting
Skin rash
Rebound
hypoglycemia
43. SIROLIMUS
Useful in Diazoxide resistant hyperinsulinemic hypoglycemia
0.5mg/m2 of body surface area/day(in one or two doses)
Alone or along with Octreotide
Acts by – inhibiting m-TOR complex pathway
May leads to reduced viability of Beta cells.
44. Surgery
Failure of medical intervention to stabilize plasma glucose levels
warrants exploration of surgery as an alternative treatment for
hypoglycemia. Specialized imaging using [18F]fluoro-L-DOPA
positron emission tomography with computed tomography
distinguishes focal from diffuse lesions in the pancreas and guides
surgical intervention.
46. Long term follow-up and evaluation
Infants with hypoglycemia exhibit a typical pattern – restricted diffusion in
occipital cortex, optic radiation and corpus callosum
Affects visuomotor and executive functons in long term.
Brainstem and cerebellum are relatively resistant.
Difficult clinically to separate isolated hypoglycaemia from hypoxic
ischemic encephalopathy plus hypoglycaemia.
Close follow-up of neurodevelopmental status is warranted
47. NEONATAL HYPERGLYCEMIA
It is relatively rare condition in neonates and is diagnosed when
whole blood glucose level >125mg/dl or plasma glucose
value>145mg/dl
48. ETIOLOGY
1. Iatrogenic – Exogenous parentral infusion of glucose, >5mg/kg/mt in preterm
infants <1000g.
2. Drugs – Glucocorticoids, caffeine, Theyophyllin, Phenytoin, Diazoxide
3. ELBW (<1000g) – variable insulin response to persistent endogenous glucose
production
4. Lipid infusion – free fatty acids are associated with increased glucose level
5. Sepsis – due to depressed insulin release
decreased glucose utilization.
elevated stress hormones, catecholamines
49. 6. Painful procedures like mechanical ventilation – catecholamine's and stress
hormones
7. Hypoxia – increased glucose production in the absence of peripheral
utilization
8. Surgical procedures – secretion of epinephrine, glucocorticoids, and
glucagon ,excess administration of iv fluid containing glucose
9. . Pancreatic lesion- aplasia, hypoplasia, absent pancreatic beta cells
10. Hyperosmolar formula infusion – associated with transient hyperglycemia
11.Immature development of glucose transporter Eg: GLUT- 4
50. NEONATAL DIABETIS MELLITES
Rare disorder
Incidence 1:300,000 to 500,000 live births
Presents with significant hyperglycemia before 1st month of life that last for at least 2 weeks,
requires insulin therapy.
most common occurs in SGA term infants.
Family history of DM seen in 1/3rd cases
Caused by defects in
insulin secretion
beta cell development
52. NDM is subclassified into
• Transient neonatal diabetes mellitus (TNDM)
• Permanent neonatal diabetes mellitus (PNDM)
PNDM - accounts for 50% of all cases of NDM
- mutations in K+ channel on pancreatic beta cells
- leads to decreased insulin secretion
53. Transient neonatal diabetes mellitus (TNDM)
Accounts for remaining half of NDM cases.
Between 60% and 80% of patients with TNDM
• Display genetic mutations
• Mostly chromosome-6 abnormalities
Course of TNDM is highly variable
• Permanent resolution within the first several weeks or months of
life to recurrence later in childhood.
54. CHALLENGES IN MANAGEMENT
Compromise of calories, if glucose is withheld
Lack of a pharmacokinetic profile for S/C administration of insulin in
neonates
Use of small doses that are highly error-prone
Limited data for dilution of Insulin's
lack of subcutaneous fat deposits in a preterm/IUGR
56. REFERENCES
1. CLOHERTY AND STARKS MANUAL OF NEONATL CARE
2. Nelson Textbook of Pediatrics 21 Edition
3. IAP Textbook of Pediatrics
4. AIIMS Protocols in Neonatology
5. neoreviews.aappublications.org January 1, 2020
6. Pediatric Endocrine Society for Evaluation and Management of
Persistent Hypoglycemia in Neonates, Infants,
and Children THE JOURNAL OF PEDIATRICS. www.jpeds.com
59. MANAGEMENT
The primary goal is to early detection of hyperglycaemia
Measure glucose level in premature infants or infants with abnormal
symptoms
Decrease the GIR and closely follow the blood glucose level
Begin parentral nutrition as early as possible in LBW
Feed if condition allows
60. Exogenous insulin therapy is been advised only if glucose value exceeds
250mg/dl
Bolus insulin infusion 0.05 to 0.1 units of regular human insulin over 15 min
every 4-6 hrs
Monitor glucose every 30min-1 hr
If glucose remain >200mg/dl after 3 bolus consider continuous infusion
61. Continuous insulin infusion
Rate of infusion is 0.05-0.2 unit/kg/hr (0.05)
Check glucose levels every 30 min until stable to adjust the infusion rate
If glucose levels remains >180mg/dl titrate in increments of 0.01 unit/kg/hr
If hypoglycemia occurs – discontinue insulin infusion ; give 10% D 2ml/kg iv
bolus.
Monitor potassium level
Monitor for rebound hyperglycaemia
62. Subcutaneous insulin lispro
Rarely used ,except in NDM
Typical dose – 0.03units/kg for glucose >200mg/dl
Rapid onset of action (15-30 mts) and peak effect is 30 mts to 21/2 hours
Do not administer frequently than every 3 hours to avoid hypoglycemia
Rotate administration site
Monitor glucose level frequently, potassium level q6h.
SULFONYLUREA .
used in long term management of infants with Kir6.2 and SUR1 defect.